RLM - Realm Therapeutics Plc

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.7489
+0.5489 (+24.95%)
As of 1:48PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close2.2000
Open2.1800
Bid2.5500 x 1000
Ask2.8600 x 1000
Day's Range2.1800 - 3.6500
52 Week Range2.0600 - 13.0000
Volume9,203
Avg. Volume10,576
Market Cap11.97M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • ACCESSWIRElast month

    Today’s Research Reports on Stocks to Watch: Viking Therapeutics and Realm Therapeutics

    NEW YORK, NY / ACCESSWIRE / September 19, 2018 / Viking Therapeutics and Realm Therapeutics were big winners in the biotech arena on Tuesday with both shares seeing big gains. Viking shares blasted north ...

  • MarketWatchlast month

    Realm Therapeutics launches review that may include a sale after disappointing trial results

    Realm Therapeutics PLC said Monday it has hired MTS Health Partners LP as an adviser as part of its strategic review that may include the potential sales of the company. The stock was inactive in premarket trade prior to a trading halt, which will be lifted at 7:30 a.m. ET. The decision to launch a strategic review followed results of a phase 2 trial of its Atopic Dermatitis treatment, which did not meet its threshold for continued investment. The company as decided to discontinue all of its drug development programs. Realm said it has implemented a cost cutting measures including a "significant reduction in headcount" to preserve capital. The company is now considered to be in a "offer period," as any discussions with third parties may be conducted in a "formal sale process" context. The stock has tumbled 69% month to date through Friday, while the iShares Nasdaq Biotechnology ETF has lost 3.6% and the S&P 500 has inched up 0.1%.

  • PR Newswirelast month

    Realm Therapeutics Provides Corporate Update and Hires Advisor to Support Strategic Review including Formal Sale Process

    MALVERN, Pa., Sept. 17, 2018 /PRNewswire/ -- Realm Therapeutics plc (NASDAQ: RLM / AIM: RLM), a biopharmaceutical company with a proprietary technology platform of stabilized high concentration hypochlorous acid (HOCl), today provides a corporate update following the August 14, 2018 announcement of top-line results of the Company's Phase 2 trial of PR022 in Atopic Dermatitis and announces the hiring of MTS Health Partners, L.P. to act as an advisor in relation to a strategic review that has been initiated by the Company, which may include the potential sale of the Company as a possible outcome. "A full analysis of our Atopic Dermatitis study results showed a statistically significant efficacy signal in a sub-population treated with the higher dose formulation.

  • PR Newswire2 months ago

    Realm Therapeutics Reports Top-line Data from Phase 2 Trial of PR022 in Atopic Dermatitis and First Half 2018 Financial Results

    Company Hosting Conference Call Today at 9:00 AM ET / 2:00 PM BST MALVERN, Pa. , Aug. 14, 2018 /PRNewswire/ -- Realm Therapeutics plc (NASDAQ:RLM / AIM:RLM), a clinical stage biopharmaceutical company ...

  • PR Newswire3 months ago

    Realm Therapeutics to Report First Half 2018 Financial Results

    MALVERN, Pa. , Aug. 7, 2018 /PRNewswire/ -- Realm Therapeutics plc (NASDAQ: RLM / AIM: RLM), a clinical stage biopharmaceutical company focused on developing novel therapeutics in immune-mediated diseases, ...

  • PR Newswire3 months ago

    Realm Therapeutics Announces Publication of Pre-Clinical Study Demonstrating Comparable Activity of PR022 and Topical Tofacitinib in the Treatment of Atopic Dermatitis

    MALVERN, Pa., July 10, 2018  /PRNewswire/ -- Realm Therapeutics plc (NASDAQ:RLM / AIM:RLM), a clinical stage biopharmaceutical company focused on developing novel therapeutics in immune-mediated diseases, today announces the publication of a pre-clinical study demonstrating comparable activity between PR022, Realm's proprietary topical gel formulation of high concentration hypochlorous acid (HOCl), and tofacitinib, a topical Janus kinase (JAK) inhibitor, in the treatment of Atopic Dermatitis. The article, "Comparison of topical tofacitinib and 0.1% hypochlorous acid in a murine atopic dermatitis model" was published in the current issue of BMC Pharmacology and Toxicology.

  • PR Newswire4 months ago

    Realm Therapeutics Announces Instructions for Exchanging Listed Ordinary Shares into Nasdaq listed ADSs

    Nasdaq: RLM) (the "Company"), a clinical stage biopharmaceutical company focused on developing novel therapeutics in immune-mediated diseases, today separately announced that in connection with a listing of American Depositary Shares ("ADSs") representing ordinary shares of nominal value of 10 pence in the capital of the Company ("Ordinary Shares") on the Nasdaq Capital Market ("Nasdaq"), the United States Securities and Exchange Commission has declared effective registration statements on Form F-1 and F-6 with respect to such securities, Nasdaq has approved the ADSs for listing, and ADSs are expected to be listed for trading on such market under the symbol "RLM" on July 5, 2018.

  • PR Newswire4 months ago

    Realm Therapeutics Announces U.S. SEC Declares Registration Statement Effective and NASDAQ Approves Listing of ADSs Representing Ordinary Shares

    Nasdaq: RLM) (the "Company") a clinical stage biopharmaceutical company focused on developing novel therapeutics in immune-mediated diseases, today announces that in connection with a listing of American Depositary Shares ("ADSs") representing the Company's ordinary shares on the Nasdaq Capital Market ("Nasdaq"), the United States Securities and Exchange Commission has declared effective registration statements on Form F-1 and F-6 with respect to such securities, Nasdaq has approved the ADSs for listing, and ADSs are expected to be listed for trading on such market under the symbol "RLM" on July 5, 2018.